

Morffi™ signal enhancement technology

AN EVOLUTION IN ASSAY PERFORMANCE

What is Morffi Technology?

Morffi signal enhancement technology achieves up to **10x more sensitivity** over existing gold conjugate assays.

Lateral flow immunoassays (LFI's) are a simple, yet powerful, diagnostic tool used for an extensive range of laboratory and point-of-care (POC) applications.

Our patent pending Morffi technology provides signal intensity enhancement and a lower limit of detection (LoD) for assays. This will enable LFI's to compete with existing laboratory based tests.

BBI Solutions are offering this technology as part of their lateral flow development service to provide your product with a competitive edge in performance.

How does it work?

Shaping the future of lateral flow assays, Morffi technology is a novel signal enhancement technique development in-house by BBI scientists.

The technology increases the availability of the antibody on the label surface, therefore increasing the opportunity for binding between the antibody and the target analyte.

Key benefits

+ 10 x increase in sensitivity



Removing the need to use BSA in your conjugate increases the availability of the binding partner on the label surface which can lead to an increase in LoD*

+ Improved signal intensity



Stronger signals generated at the current limit of detection for your test*

+ Faster time to result



Achieve results up to 4x faster*

+ BSA free conjugates



Eradicate the possibilities of cross contamination and lot to lot variation

+ Simple swap out of conjugates



No requirements to change assay material, format or complex


*Improvements observed are assay specific

RESULTS

SHAPING THE FUTURE OF
LATERAL FLOW ASSAYS

Proven performance

The results below demonstrate that the use of the *Morffi* technology leads to a significant increase in signal intensity at every analyte concentration level tested. Use of the novel blocking technology also results in a dramatic improvement in the level of detection (LoD) compared to the BSA-blocked control. The LoD achieved using the *Morffi* technology was 0.08 ng/ml, compared to 0.8 ng/ml for the BSA-blocked control, representing a 10-fold increase in the LoD for a BNP-32 assay.



FAQs

+ How can I access it?

By entering into a lateral flow licensing agreement with BBI. Each project starts with a feasibility evaluation taking between 1-2 months.

+ How easy can it be integrated into an existing test?

There is little change compared to a standard BSA blocking conjugate, therefore integration of the technology into an existing test is simple and uncomplicated, with minimal or no change to other component parts.

+ Who is it suitable for?

The technology is suitable for all types of lateral flow assays.

Register your interest today – trymorffi@bbisolutions.com or +44 (0) 2920 767 499